Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy
Wiener klinische Wochenschrift · 2025
DOI: 10.1007/s00508-025-02528-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Jiamei Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, 443003, Yichang, Hubei, China. Hauptthemen laut MEDLINE: Endothelin Receptor Antagonists, Proteinuria. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Scientific Research project of Education Department of Hubei Province, Natural Science Foundation of Yichang Municipality.
Abstract (Originalsprache)
BACKGROUND: Recent evidence increasingly confirms the therapeutic potential of endothelin receptor antagonists (ERA) in treating non-diabetic kidney nephropathy. However, clinical data in this area remain limited. Therefore, we conducted this meta-analysis to investigate the efficacy and safety of ERAs in the treatment of non-diabetic kidney nephropathy. METHODS: Randomized controlled trials were identified through PubMed, WOS, Embase, Cochrane Library and Google scholar. The initial participant characteristics and primary outcome measures were gathered, followed by the calculation of risk ratios (RR) and 95% confidence intervals (CI). Additionally, subgroup analyses were conducted to investigate the sources of heterogeneity. RESULT: In this study, seven randomized, controlled trials (RCT) were included. The results indicated that patients in the ERAs group exhibited a greater mean reduction in the urinary protein to creatinine ratio (UPCR) (standardized mean difference, MD -28.08, 95% CI -33.59 to -22.57, p < 0.001). The number of patients experiencing either complete or partial remission from proteinuria notably increased when treated with ERAs (complete remission: odds ratio, OR = 3.14, 95% CI 2.23-4.42, p < 0.001; partial remission: OR = 3.03, 95% CI 2.33-3.96, p < 0.001). Furthermore, ERAs delayed the decline in the estimated glomerular filtration rate (eGFR, MD = 3.81, 95% CI 1.71-5.90, p < 0.001). However, the incidence of edema events slightly increased in the ERA group (OR = 1.42, 95% CI 1.04-1.93, p = 0.03). CONCLUSION: The use of ERAs is more effective than regimens without ERAs in slowing the progression of non-diabetic nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, 443003, Yichang, Hubei, China.
- Division of Endocrinology, The Renhe Hospital of Three Gorges University, 443003, Yichang, Hubei, China.
- Division of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, 443003, Yichang, Hubei, China. topgan2000@163.com.
Förderung
- Scientific Research project of Education Department of Hubei Province
- Natural Science Foundation of Yichang Municipality
Zitieren
APA
Xu, J., Ma, C., Li, X., Zhang, M., & Zhu, P. (2025). Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-025-02528-4
Vancouver
Xu J, Ma C, Li X, Zhang M, Zhu P. Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-025-02528-4
BibTeX
@article{Xu2025,
author = {Xu, Jiamei and Ma, Congyuan and Li, Xuanwei and Zhang, Meng and Zhu, Ping},
title = {Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy},
journal = {Wiener klinische Wochenschrift},
year = {2025},
doi = {10.1007/s00508-025-02528-4}
}
EUVIMED